NCT04123613 - Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2019

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions

Kidney Diseases

Interventions

DRUG

DM199

A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug

Trial Locations (14)

Elixia At Clincal Renal Associates, Upland

Pines Clinical Research-Hollywood, Hollywood

Innovative Healthcare Institute, Coral Springs

Elixia at Florida Kidney Physicians-SE, Fort Lauderdale

Elixia at Florida Kidney Physicians, Temple Terrace

Research by Design LLC, Chicago

New Orleans Center for Clinical Research, an AMR Company, New Orleans

RDRI, DeSoto

Nephrotex Research Group, LLC, Dallas

Boise Kidney & Hypertension Institute, Meridian

Aventiv Research, Mesa

IMD Clinical Trials Inc, Los Angeles

Amicis Reserch Center, Northridge

Amcis Research Center, Granada Hills